Egypt cured millions of hepatitis C. Its liver cancer problem did not go away

Egypt's hepatitis C campaign delivered the largest single-country share of global HCV cures and earned WHO validation of progress toward elimination [s2]. Two reviews published within three days of each other in March describe what came next — and neither reads as a victory lap [s1][s2].

What Egypt actually accomplished

The country's HCV epidemic had an unusual origin: iatrogenic transmission during mid-twentieth-century mass campaigns of parenteral anti-schistosomal therapy, which spread the virus through reused injection equipment across an entire generation [s1][s2]. By 2008, anti-HCV prevalence reached 14.7% among adults aged 15 to 59, with roughly one in ten chronically infected [s2].

Egypt established a coordinated HCV programme in 2006 and, from 2014, scaled up direct-acting antivirals alongside nationwide testing and standardised care pathways [s2]. The two reviews give slightly different figures for the resulting mass campaign — one describes the "100 Million Health" initiative as having screened 65 million people and treated more than 4 million with cure rates exceeding 98% [s1]; the other describes the 2018–2019 "100 Million Healthy Lives" campaign as having screened 57 million citizens and treated about 4 million [s2]. The discrepancy is in the screening denominator rather than the treatment number, and either figure represents the largest single-country contribution to global HCV cures [s2]. WHO validated Egypt's progress toward elimination [s2].

Why the liver cancer burden persists

Egypt still carries one of the highest hepatocellular carcinoma burdens in the world. National estimates record 27,946 new liver cancer cases in 2022 — 18.6% of all cancer cases — and 26,971 deaths, 28.3% of all cancer deaths [s1]. Incidence and mortality run at 22.0 and 19.9 per 100,000 in men against 5.8 and 5.8 per 100,000 in women, a male predominance of roughly four to one [s1].

Two mechanisms explain why curing the virus does not immediately collapse those numbers. The first is that HCC risk persists after sustained virologic response in patients who already have advanced fibrosis or cirrhosis [s1]. Clearing the virus stops further injury; it does not reverse scarring already laid down, and the scarred liver remains a cancer-prone organ. A generation of Egyptians cured in their fifties and sixties carries that residual risk forward for decades.

The second is a change in what causes liver disease in the first place.

The handover to metabolic liver disease

As viral hepatitis recedes, metabolic dysfunction-associated steatotic liver disease — MASLD, the current term for fatty liver disease driven by obesity and metabolic dysfunction — is rising into the gap [s1][s2]. Egypt's national screening programme recorded anthropometric measurements for around 50 million adults; 39.84% met obesity criteria, 49.51% of women and 29.53% of men, with nearly three-quarters overweight or obese when projected to 2022 population counts [s2].

That is the substrate. A population with obesity prevalence approaching 40% and a heavy diabetes burden is a population in which MASLD becomes the dominant chronic liver disease more or less automatically as the viral cause is removed.

The aetiologic shift is not clean. Hepatitis B and other locally relevant risk factors continue to contribute alongside MASLD [s1], so what Egypt faces is a mixed picture rather than a straight substitution.

What the clinical response looks like

Egyptian recommendations, as described in the Liver International review, adopt a risk-assessed approach: surveillance is intensified for very high-risk groups, using ultrasonography with alpha-fetoprotein every four months in settings where HCC incidence and health-system constraints justify closer follow-up, with selective use of AFP-L3, PIVKA-II and composite scores where those are available [s1].

The four-month interval is shorter than the six-month interval used in many international guidelines, and the review presents it as a pragmatic response to a higher-incidence setting rather than as a general standard. This is a description of national recommendations, not clinical advice; screening intervals for any individual are a matter for their own clinician.

Treatment pathways are increasingly structured across Ministry of Health and university-based services, prioritising curative options in early-stage disease, transarterial chemoembolisation at intermediate stage, and modern systemic therapy for advanced disease [s1].

The gaps both reviews name

Neither review presents this as solved. Major gaps remain in surveillance coverage, timely access to high-quality imaging and biomarkers, and equitable delivery of locoregional and systemic treatments [s1]. Virologic elimination has not yet translated into measurable reductions in HCC mortality — that is stated as the priority, not the achievement [s1].

For MASLD, the Arab Journal of Gastroenterology editorial argues for building integrated primary-care pathways using simple non-invasive fibrosis triage, staged referrals, and pragmatic coverage, while consolidating HCV gains through targeted testing, micro-elimination, and post-cure risk-stratified HCC surveillance [s2].

Both are reviews and editorials synthesising national surveys and programmatic data rather than reporting new trial results, and both are explicit that they are describing a transition in progress.

Why this generalises

The editorial's closing argument is that Egypt's HCV-era infrastructure — the testing networks, the standardised care pathways, the national screening apparatus — positions it to lead a regionally scalable MASLD response [s2]. That is a claim about institutional reuse rather than about medicine: the machinery built to find and treat a virus can, in principle, be repointed at a metabolic disease.

Whether it can is the open question, and it is not one Egypt is facing alone. Several countries in the region combine high obesity prevalence with health systems built around infectious disease control.

Sources

1. Hepatocellular Carcinoma in Egypt in the Post-HCV Elimination Era: Changing Aetiology, Surveillance, and Management Pathways — Liver International, 13 March 2026 (secondary)
2. Three decades of change: schistosomiasis, hepatitis C, and the rise of metabolic dysfunction-associated steatotic liver disease in Egypt — Arab Journal of Gastroenterology, 16 March 2026 (secondary)